Bio-Tai: Plans to transfer drug variety rights and related assets and business for 450 million yuan.

Baiotai announced that the company plans to transfer its ownership rights and related assets and business of the Betadin variety to Le Pu Pharmaceuticals for a total amount of 450 million yuan, to be paid in five installments, with full payment to be made after the approval of the MAH transfer and production transfer; sales revenue will be calculated as a single-digit percentage of the annual net sales of the target drug, with a maximum of 10 years for revenue sharing. This transaction does not constitute a related party transaction or a major asset restructuring, and approval from the National Medical Products Administration is required for the transfer. The proposal has been approved by the Board of Directors and will be submitted for consideration at the 2026 second interim shareholders' meeting.